Cargando…
Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555607/ https://www.ncbi.nlm.nih.gov/pubmed/31231564 http://dx.doi.org/10.1136/esmoopen-2017-000299corr1 |
| _version_ | 1783425186092023808 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6555607 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65556072019-06-21 Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case ESMO Open Correction BMJ Publishing Group 2019-04-12 /pmc/articles/PMC6555607/ /pubmed/31231564 http://dx.doi.org/10.1136/esmoopen-2017-000299corr1 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_full | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_fullStr | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_full_unstemmed | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_short | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_sort | correction: sequential her2 blockade as effective therapy in chemorefractory, her2 gene-amplified, ras wild-type, metastatic colorectal cancer: learning from a clinical case |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555607/ https://www.ncbi.nlm.nih.gov/pubmed/31231564 http://dx.doi.org/10.1136/esmoopen-2017-000299corr1 |